INTRODUCTION
At the end of 2008, there were more than 7,000 patients awaiting KT and the median wait time was 1,660 days [1, 2] .
The increasing demand for KT requires an expanded pool of potential kidney donors. One option is anti-blood group-incompatible (ABOi) living donors. ABO incom-patibility had, until recently, been regarded as an absolute contraindication to living donor transplantation because of the high risk of hyperacute rejection [3] . Alexandre et al. [4, 5] reported the first planned successful ABOi KT using plasmapheresis (PP) and splenectomy, although the overall short-and long-term rates of graft survival were poor.
However, in the modern era of immunosuppression, the use of the protocol that includes PP plus rituximab has led to encouraging results [6] [7] [8] . Recently, ABOi KT was also started in Korea; the data is scanty [9] .
To be generally used in a donor organ program, ABOi Another 10 ABOc living donor KTs that were done during the same period had been maintained on other immunosuppressive agents, and so were excluded.
Immunosuppression
All kidney recipients of both ABOc and ABOi grafts received basiliximab (20 mg on days 0 and 4; Simulect, Novatis Pharmaceuticals Co., Basel, Switzerland) as antibody induction. Maintenance immunosuppression consisted of tacrolimus (Tacrobell, Chong Kun Dang Pharmaceuticals Co., Seoul, Korea; Prograf, Astellas Pharma Inc., Toyama, Japan), corticosteroid, and either mycophenolate mofetil (Cellcept, Hoffmann-La Roche Inc., Nutley, NJ, USA) or mycophenolate sodium (Myfortic, Novatis Pharmaceuticals Co.).
In the ABOc group, tacrolimus and corticosteroid was started on pretransplant day 2. A trough level of tacrolimus was maintained at 8 to 12 ng/mL in the first month and 6 to 8 ng/mL thereafter. Methylprednisolone was administered at a dose of 125 mg/day, 250 mg/day, 500 mg/day, 240 mg/day, and 180 mg/day on pretransplant day 2, 1, operation day, posttransplant day 1 and 2, respectively. Prednisolone (30 mg/day) was prescribed beginning at posttransplant day 3 and was rapidly tapered to a dose of The target trough level of tacrolimus and the dosage of mycophenolate mofetil or mycophenolate sodium were same as used for the ABOc recipients. Twenty milligrams of prednisolone was changed to methylprednisolone on preoperative day 2. The dosage of methylprednisolone was 125 mg/day, 250 mg/day, 1,000 mg/day, 500 mg/day, 240 mg/day, and 180 mg/day on day preoperative day 2, 1, operation day, postoperative day 1, 2, and 3, respectively. Prednisolone (30 mg/day) was prescribed beginning on thesurgery.or.kr 
Plasma exchange and intravenous immunoglobulin
All patients receiving ABOi KT were treated before transplantation with an every other day PE (one plasma volume exchanged with 5% albumin) followed by 100 mg/kg of IVIG. The final preoperative PE and all post-operative PEs were performed with donor blood type fresh frozen plasma. The number of pre-transplant PEs was determined by the baseline of ABO Ab titer [6] . The acceptant criterion of anti-blood type Ab titer was ≤1:32 at the time of transplantation. Postoperative PE was performed only if there was a rise in ABO Ab with concomitant impairment of the graft function except for the first case. ABO Ab titers were determined using an established tube test [10] .
Demographic and clinical data
To compare the baseline characteristics of two groups, the following data were collected: donor and recipient age 
Renal function
Graft function was assessed by recording serum creatinine (SCr), estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease (MDRD) formula, urine protein-to-creatinine ratio (UPCR) on post-transplantation day 7, 30, 60, and 90. Recipients who experienced allograft loss were excluded from the analysis after the point of graft loss.
Statistics
All data are presented as mean ± standard deviation.
Comparisons between the two groups were performed using Student's t test. P ＜ 0.05 was considered statistically significant.
RESULTS

Preoperative demographic and clinical factors
Donor and recipient baseline characteristics were similar in both groups, except for sensitization (PRA ≥ 20% in 41.7% of ABOi recipients and 12% of ABOc recipients) and cold ischemic time (56.3 ± 13 minutes in ABOi recipients vs. 47.1 ± 9.7 minutes in ABOc recipients; P = 0.008, respectively) ( Table 1) .
Patient characteristics, anti-blood-type antibody titer in ABOi recipients
Results are summarized in Tables 2, 3 . Twelve adult thesurgery.or.kr 
KT, kidney transplantation; PE, plasma exchange; Ab, antibody; GF, graft failure. 
Patient and graft survival and renal allograft function
Overall patient survival was 100% in both groups for 90 (Table 4) .
Acute rejection
All rejections were confirmed upon biopsy. The incidence of acute rejection was 16% and 25% in the ABOc and ABOi group, respectively (P = 0.515). In the ABOc group, seven patients experienced eight episodes of acute rejection, one acute antibody mediated rejection (AAMR) and seven acute cellular rejection. In the ABOi group, three suffered acute rejection, one AAMR and two acute cellular rejections (Table 4) .
Complications
All infectious, medical, and surgical complications are listed in Table 5 . No difference was apparent between the two groups.
There were no serious and lethal infectious compli- 
Hospitalization
The pre-transplant hospital stay was significantly longer in the ABOi group (16.3 ± 4.6 days) compared with the ABOc group (6.2 ± 2.3 days) (P = 0.003). The post-transplant hospital stay was similar between the two groups (P = 0.198).
DISCUSSION
The goal of ABOi KT is to increase the number of KTs and to avoid or shorten the time on dialysis. For ABOi donors to become widely used in KT, the allograft function and potential risks must be equal to those after ABOc KT.
Yet, comparative data is lacking. Presently, ABOi KT recipients (n = 12) were compared for 3 months after KT with 50
ABOc KT patients whose regimen had included the same basic immunosuppression. This short-term study demonstrated that the outcomes of ABOi KT using PE plus rituximab is equivalent to that from an ABOc KT in terms of patient survival, graft survival, graft function, post-operative complications, and total hospital stay.
Unfortunately, in up to one-third of cases, kidney donation is refused due to blood group incompatibility. The use of living donor KT would boost the available transplants by 10 to 20% [6, 11, 12] . Before this goal can be achieved, protocols to overcome the ABOi barrier will be necessary for successful ABOi KT. As an initial approach, PE with splenectomy was used, but more widespread implementation was frustrated by the high rates of infection and rejection [5, 13] .
However, in the modern era of immunosuppression, protocols using PP plus rituximab have led to encouraging results [6] [7] [8] .
In this study, patient and graft survival of the ABOi group for 3 months after KT was good and did not differ performing ABOi KT, the tube test is used to determine the ABO Ab titers. However, significant inter-institutional variability in the measurement of ABO Ab can occur [15] .
When different techniques were compared, only flow cytometry yielded a very consistent outcome in repeated measurements, indicating its adoption as an international standard to determine ABOi [19] [20] [21] .
It is well-known that the risk for AAMR after an ABOi KT is highest in the first 2 weeks after the operation, and can correlate with the post-operative ABO Ab titer [22, 23] . A very high incidence of graft loss occurs in patients who experienced AMR during this critical period [24] . This has prompted many centers to employ a protocol with routine fixed scheduled post-operative PP during the first 2 weeks after transplantation [25, 26] . Although a routine postoperative PP is effective to prevent acute cellular rejection, it can increase cost, prolong hospitalization, and increase the risk of PP-related complications. Recently, many centers have adopted a policy where post-operative PP is done only if there is an increase in the anti-blood type Ab titer to a certain level [15, 27] or a rise in ABO Ab titer with concomitant impairment of graft functions [7, 8] . We also performed se- We conclude that the short-term results of the ABOi KT using this regimen are equivalent to that of the ABOc KT in patient survival, graft survival, and graft function, without any serious complications.
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